At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of schizophrenia or schizoaffective disorder per DSM-IV
- ✓PANSS total score >60
- ✓PANSS positive subscale score ≥4 on two or more items
- ✓CGI score ≥4
- ✕History of unstable coronary artery disease or congestive heart failure
- ✕History of long QT syndrome, cardiac arrhythmia, or conduction delay
- ✕Baseline QTc >0.425 seconds
- ✕History of neuroleptic malignant syndrome
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pimozide Augmentation of Clozapine in Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Pimozide and Placebo for Schizophrenia and Psychotic Disorders. Completed, enrolled 76 participants across 3 sites.
Detailed Summary
This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
Study Details
Timeline
Interventions
Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.